NCT05397262Recruiting
Organ-preservative Therapy of Bladder Cancer With Radiotherapy or Radiochemotherapy Combined With Hyperthermia
Register-Trial Based on an Agreement of Health Insurances With the Department of Radiation Therapy of the University Hospital Erlangen for the Application of Regional Hyperthermia in Bladder Cancer: Organ-preservative Therapy of Bladder Cancer With Radiotherapy or Radiochemotherapy Combined With Hyperthermia
Source: ClinicalTrials.gov · Last updated 9 May 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Analysis of the efficacy and the compatibility of deep regional hyperthermia in combination with radiotherapy and chemoradiotherapy in bladder cancer
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 1000 (estimated)
- First submitted
- 10 Apr 2017
- Start date
- 29 Mar 2017
- Primary completion date
- 31 Dec 2098
- Lead sponsor
- University of Erlangen-Nürnberg Medical School
- Diseases
- Bladder cancer
- NCT number
- NCT05397262
What you commit to
- Study type: Interventional
- Planned participants: 1000
- From 29 Mar 2017 to the primary completion date, 31 Dec 2098
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Metal implants (lenght \> 2cm or dense clusters of marker clips in the pelvis)
- Patients not willing to use effective contraception during and up to 6 months after therapy
Other illness
- Pre-existing uncontrolled cardiac disease, signs of cardiac failure, or rhythm disturbances requiring therapy
- Cardiac Pacemaker
- Myocardial infarction within the past 12 months
- Congestive heart failure
- New York Heart Association (NYHA) class III or IV heart disease
- Disease that would preclude TUR, chemoradiation or deep regional hyperthermia
- Active or therapy-resistent bladder infections
Other
- Complete bundle branch block
- Pre-existing or concommitant immunodeficiency Syndrom
- Pregnant or lactating women
Who the study is looking for
- Age ≥ 18 years
- Histologically confirmed bladder cancer
- M0
- ECOG-performance status ≤ 2
- Informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dept. of Radiation Therapy, University Hospital Erlangen Coordinator of this site? Confirm its status | Erlangen | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.